TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed non-Hodgkin lymphoma

Trial Profile

TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed non-Hodgkin lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs TI-1007 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Timmune Biotech
  • Most Recent Events

    • 23 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top